Document Detail

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
MedLine Citation:
PMID:  18076664     Owner:  NLM     Status:  MEDLINE    
This study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-alpha blocker therapy. All TB cases (n = 21) complicating TNF-alpha blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-alpha antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-alpha antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed.
B Denis; A Lefort; R M Flipo; F Tubach; M Lemann; P Ravaud; D Salmon; X Mariette; O Lortholary;
Related Documents :
7035624 - Cryptococcal meningitis. a review of 32 years experience.
19460254 - Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen i...
1654364 - Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis.
20070534 - Lumbar puncture drainage with intrathecal injection of amphotericin b for control of cr...
22127044 - Long-term results of spinal cord injury therapy using mesenchymal stem cells derived fr...
3779324 - Intensive immunosuppression in intractable rheumatoid arthritis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-12-10
Journal Detail:
Title:  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases     Volume:  14     ISSN:  1198-743X     ISO Abbreviation:  Clin. Microbiol. Infect.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-10     Completed Date:  2008-09-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9516420     Medline TA:  Clin Microbiol Infect     Country:  France    
Other Details:
Languages:  eng     Pagination:  183-6     Citation Subset:  IM    
Université Paris V, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Antirheumatic Agents / adverse effects*,  therapeutic use
Antitubercular Agents / therapeutic use
Arthritis, Rheumatoid / complications,  drug therapy*
Follow-Up Studies
France / epidemiology
Immunosuppressive Agents / adverse effects,  therapeutic use
Middle Aged
Treatment Outcome
Tuberculosis / chemically induced*,  drug therapy,  mortality
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Antitubercular Agents; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the Vitek-2 extended-spectrum beta-lactamase test against non-duplicate strains of Ent...
Next Document:  Use of a multiplex PCR-based reverse line blot (mPCR/RLB) hybridisation assay for the rapid identifi...